Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Provided By GlobeNewswire
Last update: Oct 11, 2023
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1
INPEFA recently approved by FDA for treatment of heart failure
Read more at globenewswire.com
